GLUE - Company ID 0001826457
The table below shows Monte Rosa Therapeutics, Inc.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $129.88M | $224.25M | $128.10M | $54.91M | $346.07M |
| Short-term investments | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Total current assets | $393.19M | $377.44M | $236.21M | $275.89M | $348.67M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Property, plant & equipment | $25.99M | $29.48M | $33.80M | $27.07M | $12.32M |
| Goodwill | - | - | - | - | - |
| Total assets | $448.66M | $438.73M | $303.75M | $342.39M | $366.33M |
| Accounts payable | $3.55M | $17.21M | $11.15M | $7.86M | $6.56M |
| Total current liabilities | $64.21M | $156.95M | $46.59M | $25.57M | $16.64M |
| Long-term debt | - | - | - | - | - |
| Total liabilities | $215.60M | $215.80M | $124.50M | $70.98M | $18.81M |
| Retained earnings | -$477.21M | -$438.59M | -$365.89M | -$230.54M | -$122.03M |
| Total equity | $233.06M | $222.94M | $179.25M | $271.41M | $347.51M |